Clinical Research Directory
Browse clinical research sites, groups, and studies.
Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib
Sponsor: Samara State Medical University
Summary
The study will study the state of the endothelium in patients with chronic myeloid leukemia during therapy with the II generation tyrosine kinase inhibitor bosutinib. Patients will be divided into groups receiving nilotinib 800mg/day, bosutinib 500mg/day, and imatinib 600mg/day. A comprehensive examination of patients will be carried out, including a clinical examination, a study of biochemical markers of endothelial damage and the functional state of the vascular wall. An algorithm will be developed for assessing the state of endothelial function in patients with ph-positive chronic myeloid leukemia in the chronic phase when using the second-generation tyrosine kinase inhibitor bosutinib.
Official title: Condition Vasoregulation Function Endothelium in Patients With Chronic Myeloid Leukemia (CML) Getting Tyrosine Kinase Inhibitor (TKI) II Generation Bosutinib
Key Details
Gender
All
Age Range
40 Years - 60 Years
Study Type
OBSERVATIONAL
Enrollment
105
Start Date
2022-10-01
Completion Date
2025-09-15
Last Updated
2024-12-16
Healthy Volunteers
No
Conditions
Interventions
taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry
In the study, blood will be taken from patients with chronic myelogenous leukemia in the chronic phase to determine biochemical parameters (endothelin-1, homocysteine, VEGF (vascular endothelial growth factor)), as well as a study of microcirculation in these groups of patients using the method of laser Doppler flowmetry, to study the function of the endothelium.
Locations (2)
National Medical Research Centre for Hematology
Moscow, Russia
Samara State Medical University
Samara, Russia